; Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

VIEWS: 57 PAGES: 5

Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma) Summary The group of cancers that originate in the lymphatic system are known as lymphoma. Lymphoma is broadly classified into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. In 2010, more than 16,887 new cases of Hodgkin lymphoma and 139,507 new cases of non-Hodgkin lymphoma were diagnosed in the top seven markets (the US, the UK, Germany, France, Italy, Spain and Japan). The treatment for Hodgkin lymphoma is dominated by the combination of generic drugs like doxorubicin, bleomycin, vinblastine, dacarbazine, mechlorethamine, etoposide, vincristine, prednisone, cyclophosphamide, procarbazine, chlorambucil, methylprednisolone, cytarabine, cisplatin and dexamethasone. The treatment for non-Hodgkin lymphoma is dominated by Rituxan (rituximab) followed by Velcade (bortezomib), Bexxar (tositumomab and Iodine I 131 tositumomab), Zevalin ([90Y]-ibritumomab tiuxetan), Treanda (bendamustine hydrochloride), Folotyn (pralatrexate) and Mozobil (plerixafor). Scope - There is a high unmet need, both in Hodgkin lymphoma and non-Hodgkin lymphoma, which demands novel agents with improved efficacy and toxicity profiles. The unmet need is very high particularly in the treatment of relapsed and refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients. The relapse rates are 30% and 50% for Hodgkin lymphoma and ALCL respectively with limited treatment options representing a significant unmet need. Autologous stem cell transplantation is the only available treatment for relapsed patients. The survival rates in the relapsed patients are less than a year. Reasons to buy - Impact analysis of Brentuximab Vedotin as a First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)

More Info
  • pg 1
									           Brentuximab Vedotin – First Treatment Option for Relapsed
           Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
                     (Subset of Non-Hodgkin Lymphoma)
       Reference Code: GDHC0036VPT                                                                                                      Publication Date: May 2011


       1         Table of Contents                                                              2       Summary
       1 Table of Contents............................................................. 1       The group of cancers that originate in the lymphatic system are
       2 Summary ......................................................................... 1    known as lymphoma. Lymphoma is broadly classified into two
       3 Overview.......................................................................... 2   types: Hodgkin lymphoma and non-Hodgkin lymphoma. In
        3.1 Disease Overview ...................................................... 2           2010, more than 16,887 new cases of Hodgkin lymphoma and
        3.2 Epidemiology ............................................................. 2        139,507 new cases of non-Hodgkin lymphoma were diagnosed
        3.3 Current Therapy Options ............................................ 2
        3.4 Unmet Need .............................................................. 3         in the top seven markets (the US, the UK, Germany, France,
        3.5 Brentuximab Vedotin – First Drug to Treat Relapsed or                               Italy, Spain and Japan). The treatment for Hodgkin lymphoma is
             Refractory Hodgkin Lymphoma and ALCL patients...... 3                              dominated by the combination of generic drugs like doxorubicin,
        3.6 Current Market........................................................... 4         bleomycin,     vinblastine,   dacarbazine,    mechlorethamine,
       4 Appendix.......................................................................... 4   etoposide,     vincristine,  prednisone,     cyclophosphamide,
        4.1 Methodology .............................................................. 4        procarbazine, chlorambucil, methylprednisolone, cytarabine,
          4.1.1    Coverage .......................................................... 4
                                                                                                cisplatin and dexamethasone. The treatment for non-Hodgkin
          4.1.2    Secondary Research ......................................... 4
          4.1.3    Primary Research.............................................. 5             lymphoma is dominated by Rituxan (rituximab) followed by
          4.1.4    Expert Panel Validation ..................................... 5              Velcade (bortezomib), Bexxar (tositumomab and Iodine I 131
        4.2 Contact Us................................................................. 5       tositumomab), Zevalin ([90Y]-ibritumomab tiuxetan), Treanda
        4.3 Disclaimer.................................................................. 5      (bendamustine hydrochloride), Folotyn (pralatrexate) and
                                                                                                Mozobil (plerixafor).
                                                                                                There is a high unmet need, both in Hodgkin lymphoma and
                                                                                                non-Hodgkin lymphoma, which demands novel agents with
                                                                                                improved efficacy and toxicity profiles. The unmet need is very
                                                                                                high particularly in the treatment of relapsed and refractory
                                                                                                Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL)
                                                                                                patients. The relapse rates are 30% and 50% for Hodgkin
                                                                                                lymphoma and ALCL respectively with limited treatment options
                                                                                                representing a significant unmet need. Autologous stem cell
                                                                                                transplantation is the only available treatment for relapsed
                                                                                                patients. The survival rates in the relapsed patients are less
                                                                                                than a year.
                                                                                                Brentuximab Vedotin (SGN-35) is an antibody-drug conjugate
                                                                                                (ADC) targeting CD30 which is a defining marker of Hodgkin
                                                                                                lymphoma. Seattle Genetics and Millennium: the Takeda
                                                                                                Oncology Company are jointly developing Brentuximab Vedotin.
                                                                                                Seattle Genetics filed for two biologics license applications
                                                                                                (BLA) for Brentuximab Vedotin. One BLA was filed to treat the
                                                                                                patients with relapsed refractory Hodgkin lymphoma and the
                                                                                                second BLA was filed for the treatment of refractory systemic
                                                                                                ALCL. On May 2, 2011 the Food and Drug Administration
                                                                                                (FDA) accepted the BLA filing of Brentuximab Vedotin and has
                                                                                                granted a six-month priority review of both the applications and
                                                                                                an action on these BLAs is expected by August 30, 2011.
                                                                                                Brentuximab Vedotin was granted an orphan drug designation
                                                      
								
To top